Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAT3306 vs Keytruda in Resected Early-Stage NSCLC
NCT07180862Phase 1Active, not recruiting
- Sponsor
- Bio-Thera Solutions, Ltd.
- Start
- Oct 2025
- Primary completion
- Feb 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of pembrolizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Bio-Thera Solutions, Ltd. Primary endpoint: Pharmacokinetic equivalence. Started Oct 2025; status: active, not recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07180862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07180862.